Logical Assessment
Long/short equity, biotech, small-cap, micro-cap

GlassesOff: The Most Disruptive Technology In Mobile

Like many other Seeking Alpha contributors, I'm a huge fan of companies with management with proven track records in creating shareholder value. Unquestionably, Shai Novik, founder and president of Prolor Biotech has done so.

Last year I wrote that Prolor Biotech (NYSEMKT:PBTH) was a prime candidate for a buyout, based on its valuation, clinical assets, and investor Philip Frost's involvement with both Prolor and Teva (NYSE:TEVA). Although Teva turned out not to be the buyer, my original thesis played out almost exactly: Prolor was acquired by OPKO Health (NYSEMKT:OPK) earlier this year. (Frost is also the CEO and Chairman of OPKO.) For readers who bought Prolor when I wrote the article, the value has...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details